Technology’s ability to accelerate the pace of innovation while reducing the cost is changing the dynamic of the struggle ...

Since the Orphan Drug Act was passed in 1983, pharmaceutical companies have increasingly focused on developing treatments for ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical ...

The US Food and Drug Administration (FDA) has approved Organon’s Vtama (tapinarof) cream, 1% to treat atopic dermatitis in ...

Moving Minds Moving Minds is an award-winning on demand marketing+technology agency enabling forward-thinking companies to get to market faster and smarter with ‘Growth as a Managed Service,’ a ...

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis ...

Gilead Sciences has appointed Dietmar Berger as chief medical officer and a member of its senior leadership team. Berger, who ...

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice Research conducted ...

Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...